A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2018
At a glance
- Drugs PL MLP (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Lipomedix Pharmaceuticals
- 09 Jul 2018 Status changed from active, no longer recruiting to completed.
- 12 Feb 2018 Planned End Date changed from 1 Sep 2018 to 1 May 2018.
- 12 Feb 2018 Status changed from recruiting to active, no longer recruiting.